The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | RUBY & EdiTHAL trials: evaluating the safety and efficacy of EDIT-301 in SCD & thalassemia
Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, shares insights into the RUBY and EdiTHAL trials (NCT04853576; NCT05444894), which are evaluating the safety and efficacy of EDIT-301, a novel investigational gene-edited autologous product, in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia. In both trials, EDIT-301 has demonstrated promising safety and tolerability, with no severe adverse events (AEs) observed so far. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: SOBI, Sanofi
Honoraria: Vertex
Research Funding: EDITAS
